422 



SUBJECT INDEX 



Runt disease, 



organ-enlargement assays, 246- 



251, 257, 266-267 

 purity of cells used, 241-242 

 ■ role of cell dosage, 242-246, 255 

 weight-gain assay, 246-251, 266 

 due to injection of spleen cells, 196- 

 200, 343, 352-360, 380 

 effect of dosage, 358-359 

 route of injection, 358-359 

 due to presensitized cells, treated 



with amethopterin, 381 

 due to thoracic duct lymphocytes, 



237 _ 

 evaluation of, 294 

 general features, 355-360 

 index of runting, 198 

 in terms of antigenic strength, 196- 



200 

 kidney weight in, 248-250, 266-267 

 Hver weight in, 248-250, 257, 266- 



267 

 mechanism of, 317-3 1 8 

 modification of, 350-383 

 mortahty rates, 298-307, 313, 317, 



324 

 pathological features, 3 5 5-3 60 

 protection against, 286-327 

 by enhancement, 299-300 

 difference in sera used, 301-302, 



310 

 experimental methods, 290-297 

 factors of variation, 301-302 

 haemagglutination test of sera, 



310-311 

 immunological specificity of sera 



used, 310-317 

 immunotoxicity of sera, 31 1-3 13 

 importance of dose of serum, 



302-303 

 increase in tolerance, 313-316 

 mechanism, 287, 318-322 

 number of injections needed, 



303-304 



Runt disease, 



presensitization, 326 



role of active enhancement, 319- 



322 

 weight curves, 307-310, 322 

 relation to tolerance, 343-348 

 relation with enhancement, 343-348 

 spleen weight in, 248-250, 257 

 splenomegaly in, 196, 206 

 survival times, 382-383 

 thymus in, 327, 401 

 transfer of, 373-374, 375, 379 

 treatment of, 351-352 



by adoptive transfer of protective 



cells, 360-365 

 non-specific methods, 367-373 

 with 6 - (i - methyl - 4 - nitro- 

 imidazolyl) thiopurine, 3 52, 

 369-370 

 with amethopterin, 370-373, 376, 



381 

 with antiserum, 365-367, 381 

 with cortisone, 367-369 

 with cytotoxic antiserum, 365- 



366, 381 

 v^th X-irradiation, 369 

 weight curves in, 307-310, 322, 356 

 weight-gain assay, 351, 361, 362, 

 368, 372 



Sarcoma, metastases from in radiation 

 cliimeras, 164-169 

 transplantation of, in radiation 

 chimeras, 164-169, 170, 180 

 Sarcoma i, 

 isoantigenic lipoprotein from, 72- 

 89 

 activity of, 76-77 

 chemical composition of, 79 

 electrophoresis, 76-77 

 isolation of, 73-77 

 modification by snake venom, 



80-85 

 properties of, 77-80 



